Literature DB >> 10580414

Evidence for glucose/hexosamine in vivo regulation of insulin/IGF-I hybrid receptor assembly.

M Federici1, A Giaccari, M L Hribal, B Giovannone, D Lauro, L Morviducci, L Pastore, G Tamburrano, R Lauro, G Sesti.   

Abstract

Hybrid receptors composed of an insulin alphabeta-hemireceptor and a type 1 IGF alphabeta-hemireceptor are formed in tissues expressing both molecules. We recently reported an increased hybrid receptor expression in skeletal muscle of type 2 diabetic patients that is inversely correlated with in vivo insulin sensitivity. It is unclear whether these changes were due to primary abnormalities or to secondary derangements acting in vivo, such as hyperglycemia. To address this, we determined abundance of hybrids in skeletal muscle from three groups of rats: controls, diabetic (90% pancreatectomy), and diabetic treated with phlorizin to normalize plasma glucose levels. We found that the abundance of hybrid receptors was higher in diabetic rats compared with control and phlorizin-treated diabetic rats (percentage of 125I-insulin bound versus total added radioactivity [B/T] = 1.8+/-0.11, 0.4+/-0.01, and 0.32+/-0.04, respectively; P < 0.0001). Fasting plasma glucose levels were positively correlated with hybrids abundance (r = 0.77, P < 0.002). Hybrid receptor protein content, assessed by immunoblotting, was 2.4-fold higher in diabetic rats as compared with control and phlorizin-treated diabetic rats. Because it has been shown that some of the regulatory effects of glucose may be mediated by the glucosamine pathway, we subsequently determined the effect of an in vivo glucosamine infusion on hybrid receptor formation. We found that abundance of hybrids was significantly higher in muscle from glucosamine-treated rats compared with control rats (B/T = 0.17+/-0.02 and 0.11+/-0.01, respectively; P < 0.009). Quantitation of hybrid content by immunoblotting revealed that their abundance was 1.9-fold higher in glucosamine-treated rats. The results demonstrate that 1) elevated glucose levels in diabetic rats are associated with increased expression of hybrid receptors in muscle, 2) correction of hyperglycemia with phlorizin completely reverses increased expression of hybrids, and 3) glucosamine infused into control rats mimics the effects of hyperglycemia on hybrid receptor formation. Thus, the results support the hypothesis that glucose acting, at least in part, through the glucosamine pathway may play an important role in regulating hybrid receptor assembly in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580414     DOI: 10.2337/diabetes.48.12.2277

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

Review 1.  Insulin receptor signaling in normal and insulin-resistant states.

Authors:  Jérémie Boucher; André Kleinridders; C Ronald Kahn
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-01-01       Impact factor: 10.005

Review 2.  Recent developments in the structural characterisation of the IR and IGF1R: implications for the design of IR-IGF1R hybrid receptor modulators.

Authors:  Samuel J Turvey; Martin J McPhillie; Mark T Kearney; Stephen P Muench; Katie J Simmons; Colin W G Fishwick
Journal:  RSC Med Chem       Date:  2022-02-21

Review 3.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

Review 4.  The IGF-1 receptor and regulation of nitric oxide bioavailability and insulin signalling in the endothelium.

Authors:  V Kate Gatenby; Helen Imrie; Mark Kearney
Journal:  Pflugers Arch       Date:  2013-01-22       Impact factor: 3.657

5.  The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium.

Authors:  Afroze Abbas; Helen Imrie; Hema Viswambharan; Piruthivi Sukumar; Adil Rajwani; Richard M Cubbon; Matthew Gage; Jessica Smith; Stacey Galloway; Nadira Yuldeshava; Matthew Kahn; Shouhong Xuan; Peter J Grant; Keith M Channon; David J Beech; Stephen B Wheatcroft; Mark T Kearney
Journal:  Diabetes       Date:  2011-06-15       Impact factor: 9.461

6.  Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.

Authors:  Cécile Pierre-Eugene; Patrick Pagesy; Tuyet Thu Nguyen; Marion Neuillé; Georg Tschank; Norbert Tennagels; Cornelia Hampe; Tarik Issad
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

Review 7.  Insulin-like growth factor-1 deficiency and metabolic syndrome.

Authors:  G A Aguirre; J Rodríguez De Ita; R G de la Garza; I Castilla-Cortazar
Journal:  J Transl Med       Date:  2016-01-06       Impact factor: 5.531

8.  Effects of obesity on insulin: insulin-like growth factor 1 hybrid receptor expression and Akt phosphorylation in conduit and resistance arteries.

Authors:  Romana S Mughal; Katherine Bridge; Irma Buza; Rita Slaaby; Jesper Worm; Gro Klitgaard-Povlsen; Henning Hvid; Marianne Schiødt; Richard Cubbon; Nadira Yuldasheva; Anna Skromna; Natallia Makava; Grith Skytte-Olsen; Mark T Kearney
Journal:  Diab Vasc Dis Res       Date:  2018-10-08       Impact factor: 3.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.